Jin Xia
No. 1 Jianshe East Road
Zhengzhou, 450052, China
Zhengzhou, 450052, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Construction and verification of 5-year survival prediction model for post-op ESCC patients.
Journal: Frontiers in oncology
Published: January 28, 2026
Differences in immune indicators among normal, high-risk, and esophageal cancer populations and development of a predictive model.
Journal: Frontiers in immunology
Published: October 13, 2025
EVA1A facilitates glycolysis in esophageal squamous cell carcinoma to boost PLAU histone lactylation and dampen CD8+ T cell activity.
Journal: Expert review of clinical immunology
Published: August 19, 2025
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 11, 2025
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.
Journal: Molecular cancer
Published: January 25, 2025
Uniformly aligned Ag NPs/graphene paper for enhanced SERS detection of pesticide residue.
Journal: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Published: September 03, 2024
First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.
Journal: Signal transduction and targeted therapy
Published: June 03, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 02, 2024
Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study.
Journal: The oncologist
Published: May 31, 2024
Radiomics model based on contrast-enhanced CT texture features for pretreatment prediction of overall survival in esophageal neuroendocrine carcinoma.
Journal: Frontiers in oncology
Published: May 18, 2023
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: August 19, 2021
Last Updated: 09/26/2026